Browse by UCL people
Group by: Type | Date
Number of items: 18.
Article
Dehbi, Hakim‐Moulay;
Embleton‐Thirsk, Andrew;
McCaw, Zachary Ryan;
(2022)
Sample size calculation for randomized selection trials with a time‐to‐event endpoint and a margin of practical equivalence.
Statistics in Medicine
10.1002/sim.9490.
(In press).
|
|
Ehrenstein, M;
Shipa, M;
Yeoh, S-A;
Embleton-Thirsk, A;
Mukerjee, D;
(2021)
The synergistic efficacy of hydroxychloroquine with methotrexate is accompanied by increased erythrocyte mean corpuscular volume.
Rheumatology
, 61
(2)
pp. 787-793.
10.1093/rheumatology/keab403.
|
|
Embleton-Thirsk, A;
Deane, E;
Townsend, S;
Farrelly, L;
Popoola, B;
Parker, J;
Rustin, G;
... Kaplan, R; + view all
(2019)
Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application.
Clinical Trials
, 16
(5)
pp. 502-511.
10.1177/1740774519862528.
|
 |
|
González Martín, A;
Oza, A;
Embleton, AC;
Pfisterer, J;
Ledermann, J;
Pujade-Lauraine, E;
Kristensen, G;
... Perren, T; + view all
(2019)
Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
Gynecologic Oncology
, 152
(1)
10.1016/j.ygyno.2018.08.036.
|
|
|
Halvorsen, AR;
Kristensen, G;
Embleton, A;
Adusei, C;
Pilar Barretina-Ginesta, M;
Beale, P;
Helland, A;
(2017)
Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients.
Disease Markers
, Article 3098542. 10.1155/2017/3098542.
|
|
Hawarden, Amy;
Price, Marcus;
Russell, Bryn;
Wilson, Godfrey;
Farrelly, Laura;
Embleton-Thirsk, Andrew;
Parmar, Mahesh;
(2023)
A three protein signature fails to externally validate as a biomarker to predict surgical outcome in high-grade epithelial ovarian cancer.
PLoS ONE
, 18
(3)
, Article e0281798. 10.1371/journal.pone.0281798.
|
|
Jahangiri, M;
Bilkhu, R;
Embleton-Thirsk, A;
Dehbi, H-M;
Mani, K;
Anderson, J;
Avlonitis, V;
... Freemantle, N; + view all
(2021)
Surgical aortic valve replacement in the era of transcatheter aortic valve implantation: a review of the UK national database.
BMJ Open
, 11
(10)
, Article e046491. 10.1136/bmjopen-2020-046491.
|
|
|
Kommoss, S;
Winterhoff, B;
Oberg, A;
Konecny, GE;
Wang, C;
Riska, SM;
Fan, JB;
... Pfisterer, J; + view all
(2017)
Bevacizumab may differentially improve ovarian cancer outcome in patients with proliferative and mesenchymal molecular subtypes.
Clinical Cancer Research
, 23
(14)
pp. 3794-3801.
10.1158/1078-0432.CCR-16-2196.
|
|
Ledermann, JA;
Embleton, AC;
Raja, F;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
... Collaborators, I; + view all
(2016)
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet
, 387
(10023)
pp. 1066-1074.
10.1016/S0140-6736(15)01167-8.
|
|
Ledermann, JA;
Embleton-Thirsk, AC;
Perren, TJ;
Jayson, GC;
Rustin, GJS;
Kaye, SB;
Hirte, H;
... ICON6 collaborators, .; + view all
(2021)
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
ESMO Open
, 6
(2)
, Article 100043. 10.1016/j.esmoop.2020.100043.
|
|
|
Oza, AM;
Cook, AD;
Pfisterer, J;
Embleton, A;
Ledermann, JA;
Pujade-Lauraine, E;
Kristensen, G;
... ICON7, trial investigators; + view all
(2015)
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Lancet Oncology
, 16
(8)
pp. 928-936.
10.1016/S1470-2045(15)00086-8.
|
|
|
Schrag, Anette;
Carroll, Camille;
Lewis, Glyn;
Serfaty, Marc;
Duncan, Gordon;
Molloy, Sophie;
Whipps, John;
... Embleton-Thirsk, Andrew; + view all
(2025)
Effectiveness of Escitalopram and Nortriptyline on Depressive Symptoms in Parkinson's disease: the ADepT-PD RCT pilot.
Health Technology Assessment
, 29
(57)
, Article 75. 10.3310/HFDO7575.
|
 |
|
Shipa, M;
Embleton-Thirsk, A;
Parvaz, M;
Santos, LR;
Muller, P;
Chowdhury, K;
Isenberg, DA;
... BEAT-LUPUS Investigators; + view all
(2021)
Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial.
Annals of Internal Medicine
, 174
(12)
pp. 1647-1657.
10.7326/M21-2078.
|
|
Shipa, Muhammad;
Santos, Liliana R;
Nguyen, Dao X;
Embleton-Thirsk, Andrew;
Parvaz, Mariea;
Heptinstall, Lauren L;
Pepper, Ruth J;
... Ehrenstein, Michael R; + view all
(2022)
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial.
The Lancet Rheumatology
10.1016/s2665-9913(22)00332-0.
(In press).
|
|
Stark, D;
Cook, A;
Brown, J;
Brundage, M;
Embleton, A;
Kaplan, R;
Raja, F;
... Ledermann, J; + view all
(2017)
Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.
Cancer
, 123
(14)
pp. 2752-2761.
10.1002/cncr.30657.
|
Conference item
|
Cook, A;
Embleton, A;
Jayson, G;
Kaplan, R;
Kristensen, G;
Parmar, MK;
Pfisterer, J;
... Perren, T; + view all
(2017)
ICON7: Ovarian cancer, platinum second-line chemotherapy and overall survival.
Presented at: 42nd ESMO Congress (ESMO 2017), Madrid, Spain.
|
|
Embleton, AC;
Clark, E;
Townsend, S;
Farrelly, L;
Jones, C;
Kaplan, R;
(2015)
Impact of retrospective data verification on the results of the academic-led ICON6 trial.
Presented at: 3rd International Clinical Trials Methodology Conference, Glasgow, UK.
|
|
Thesis
|
Embleton-Thirsk, Andrew;
(2021)
Identifying, profiling and learning from non-commercial clinical trials used in regulatory submissions.
Doctoral thesis (Ph.D), UCL (University College London).
|
